Abstract:Lisda Amalia Department of Neurology, The First Affiliated Hospital of Faculty of Medicine, Universitas Padjadjaran/RSUP dr. Hasan Sadikin, Bandung, Indonesia Correspondence: Lisda Amalia Jl.Pasteur 38, Bandung, 40161, Indonesia Email Introduction: Blockage of the cerebral arteries due to thrombosis and embolism resulting in decreased blood flow to the brain, reduced oxygen supply to the brain, resulting in neuronal damage and causes astrocyte cells to secrete glial fibrillary acidic protein (GFAP). The objective of this study was to determine the correlation between GFAP levels serum and clinical outcome in patients with acute ischemic stroke. Methods: This was observational with a cross-sectional design on acute ischemic stroke patients confirmed by CT scans and divided into large vessel occlusion and small-vessel occlusion. Clinical outcome was measured using the National Institutional Health Stroke Scale (NIHSS) tool. Statistical analysis uses Spearman's rank correlation test and Mann Whitney's test, significant if p < 0.05. Results: After collecting 33 research subjects, we found 16 people with large vessel occlusion and 17 people with small vessel occlusion. Serum GFAP levels were 0.2– 1.9 ng/mL, 9.1% with a mild neurological deficit, 45.45% were moderate neurological deficits, and 45.45% were severe neurological deficits. There was a significant positive correlation (r = 0.522; p = 0.002) between serum GFAP levels and the degree of neurological deficit in ischemic stroke patients. There was a statistically significant difference between serum GFAP levels in ischemic stroke patients with CT scan results of large artery occlusion compared to small artery occlusion (0.7 vs 0.4ng/mL; p = 0.001). Conclusion: There was a positive correlation between GFAP level serum and NIHSS score on acute ischemic stroke. The higher the value of GFAP serum level, the higher the value for NIHSS and correlated with stroke severity and the extent of brain damage in ischemic stroke patients. Keywords: GFAP, clinical outcome, acute ischemic stroke, small vessel occlusion, large vessel occlusion Stroke is a neurological emergency that arises suddenly and is the 3rd cause of death in the world after heart disease and cancer. 1 Ischemic stroke is the most common type of stroke, accounting for 87% of all strokes worldwide. Impaired blood-brain barrier permeability causes GFAP to diffuse into the cerebrospinal fluid and then enter the blood circulation to detect GFAP levels in the blood. GFAP levels can begin to be detected in the blood after 12 hours of the onset of ischemic stroke and reach the highest levels after 48 hours of the onset of ischemic stroke. 2,3 There is hyperreactivity of astrocytes as a result of glutamate excitotoxicity, which can cause changes in astrocytes, namely astrocytes experience hypertrophy and proliferation which is referred to as the astrogliosis process in acute ischemic stroke. Prolonged astrogliosis in patients with brain ischemia can increase neuronal death and exacerbate brain tissue degeneration. This astrogliosis process is characterized by a rapid and high increase in GFAP levels because damaged astrocytes secrete GFAP. Astrocytes are cells that make up the blood-brain barrier, so if there is damage to the blood-brain barrier, it will cause GFAP levels to increase and enter the bloodstream. 4 GFAP level serum can be used to assess neurologic deficits, monitor therapy, and prognosticate ischemic stroke. In ischemic stroke, the greater the damage to neurons and neuroglia, the serum GFAP levels will increase, and there is a relationship between high GFAP levels and the severity of the neurological deficit and the extent of brain damage in ischemic stroke patients. The larger the infarct area, the higher the serum GFAP level and NIHSS score. 3 Based on the above framework, this study aims to determine the correlation between serum GFAP levels and clinical outcomes based on the NIHSS score in ischemic stroke patients. It was an observational correlative analysis with a cross-sectional design at RSUP. Dr. Hasan Sadikin from June 2015 to November 2015. The research subjects were patients diagnosed with ischemic stroke confirmed by CT scan who came to the hospital within five days after stroke onset and were grouped into large vessel occlusion and small-vessel occlusion based on clinical symptoms and imaging. We exclude the presence of a history of previous stroke, head trauma, patients with glioblastoma multiforme. The results of the NIHSS criteria assessment are scores, namely a score of 12 indicating a severe neurological deficit. Examination -Abstract Truncated-

Dynamic Changes of Serum Glial Fibrillary Acidic Protein Content in Patients with Brain Injury and Their Cllnical Significance

Clinical significance of serum glial fibrillary acidic protein level in middle-aged and elderly patients with Parkinson's disease

Glial Fibrillary Acidic Protein As a Biomarker in Severe Traumatic Brain Injury Patients: a Prospective Cohort Study

Dynamic changes and its clinical significance of serum glial fibrillary acidic protein content in patients with acute cerebral infarction

Relationship between cerebrospinal fluidα-Synuclein and prognosis of patients with traumatic brain injury

Early Changes of Endothelin, Nitric Oxide and Arginine-Vasopressin in Patients with Acute Cerebral Injury.

Changes in the levels of serum glial fibrillary acidic protein and the correlation with outcomes in severe traumatic brain injury patients

Glial Fibrillary Acidic Protein Serum Level as a Predictor of Clinical Outcome in Ischemic Stroke

Relationship study between serum brain red protein content and the de-gree of nerve injury in patients with brain injury

Study of Dynamics of Glial Fibrillary Acidic Protein and Tumor Necrosis Factor-α in Serum of Patients with Acute Cerebral Infarction

Plasma Glial Fibrillary Acidic Protein (GFAP) as a Biomarker of Acute Focal Brain Injury

Ability of Serum Glial Fibrillary Acidic Protein, Ubiquitin C-Terminal Hydrolase-L1, and S100B To Differentiate Normal and Abnormal Head Computed Tomography Findings in Patients with Suspected Mild or Moderate Traumatic Brain Injury

The Change and Clinical Significance of Serum Aquaporin-4 and Pnf-H in Patients with Moderate and Severe Traumatic Brain Injury

Serum Concentrations of Ubiquitin C-Terminal Hydrolase-L1 and Glial Fibrillary Acidic Protein after Pediatric Traumatic Brain Injury

Development of a time-resolved immunochromatographic test strip for rapid and quantitative determination of GFAP in serum

Integrated Assessment of GFAP and UCH-L1 for their utility in severity assessment and outcome prediction in Traumatic Brain Injury

The study on serum levels of tau and A-beta 42 in patients with brain injury

Glial Fibrillary Acidic Protein (GFAP): Neuroinflammation Biomarker in Acute Ischemic Stroke

Panel of serum protein biomarkers to grade the severity of traumatic brain injury

Association of Blood and Cerebrospinal Fluid IgG Contents and Severity of Craniocerebral Injury

Expression of Acidic Fibrillar Protein and Neuroglobin in Thrombolytic Patients in Ischemic Stroke